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Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients with newly diagnosed
symptomatic multiple myeloma (MM). The introduction into clinical practice of novel agents, such as the proteasome inhibitor
bortezomib and the immunomodulatory derivatives (IMiDs) thalidomide and lenalidomide, has signiﬁcantly contributed to
major advances in MM therapy and prognosis. These novel agents are incorporated into induction regimens to enhance the
depth of response before ASCT and further improve post-ASCT outcomes. Between January 2000 and November 2011, 65
patients with MM were transplanted in the Department of Biomedical Science and Clinical Oncology at the University of Bari.
According to Durie-Salmon, 60 patients had stage III of disease and 5 stage II. Only 7 patients were in stage B (renal failure).
Induction regimens that were administered in two or more cycles were VAD (vincristine, adriamycin, and dexamethasone),
Thal-Dex (thalidomide, dexamethasone), Len-Dex (lenalidomide, dexamethasone), Vel-Dex (bortezomib, dexamethasone), VTD
(bortezomib,thalidomide,anddexamethasone),andPAD(bortezomib,pegylatedliposomaldoxorubicin,anddexamethasone).In
mobilization procedure, the patients received cyclophosphamide and granulocyte colony-stimulating factor (G-CSF). The number
of cells collected through two or more leukapheresess, response after induction, and toxicity were evaluated to deﬁne the more
adequate up-front induction regimen in transplantation-eligible MM patients.
1.Introduction
Over the last decade, high-dose chemotherapy followed by
ASCT has been considered the standard of care for younger
patients with newly diagnosed MM, based on the increased
rate of complete response (CR), prolonged overall survival
(OS), and reduced side eﬀects compared with conventional
chemotherapy in several randomized studies [1–4]. Patients
who are eligible for early ASCT typically receive a limited
number of cycles of induction therapy to reduce tumor cell
mass and bone marrow plasma cell inﬁltration before col-
lection of peripheral blood stem cells [5]. Compared with
conventional treatments used in the past, a number of novel
agents are now available which aﬀect increased rates of
CR [6–8]. The reach of CR after both induction therapy
and ASCT is one of the strongest predictors of long-term
outcomes and represents a major endpoint of the treatment
strategy in younger patients together with maintenance of a
durable CR [5].
The initial rationale for the use of IMiDs in MM was
their known antiangiogenic activity, considered the primary
role of increased angiogenesis in MM bone marrow [9,
10]. Further investigations have shown that besides their
direct eﬀect on MM plasma cells (PCs) thalidomide and
lenalidomide, they abrogate the adhesion of MM cells to
the bone marrow stromal cells and block the secretion of
growth factors, survival factors, angiogenic cytokines (inter-
leukin (IL)-6, tumor necrosis factor (TNF)-alpha, vascular
endothelial growth factor (VEGF), and ﬁbroblast growth factor
(FGF)-2) triggered by the cross talk between tumor cells
and their microenvironment [11, 12]. Additionally these
agents signiﬁcantly modulate the host immune response by
expanding the number and the function of natural killer
(NK) cells, improving the dendritic cell (DC) functions, and2 Stem Cells International
Table 1: Patients’ characteristics.
Characteristics Total number of patients Treated with bortezomib Treated with lenalidomide Treated with other agents
Numbers 65 18 18 29
Sex, M/F 44/21 10/8 11/7 23/6
Age
Median (range) years 56.5 (48–65) 56 (48–64) 58 (51–65) 57.5 (50–65)
Monoclonal component
IgG/IgA/κ/λ 37/19/6/3 9/5/1/3 10/6/2/0 18/8/3/0
Durie-Salmon stage
I/II/III 0/5/60 0/0/18 0/2/16 0/3/26
A/B 58/7 14/4 17/1 27/2
ISS stage
1/2/3 20/27/18 6/7/5 8/6/4 6/14/9
Mobilizing chemotherapy
one/two 46/19 13/5 10/8 23/6
Number of leukapheresis
Two/three 31/34 18/0 2/16 11/18
enhancing T-cellfunctions by providing T-cellcostimulatory
signals through B7/CD28 pathways [13].
Bortezomib is the ﬁrst proteasome inhibitor used in
clinical practice in MM since the discovery of its antitumoral
mechanisms: the blockade of NF-κB activation and the IL-6
paracrine loop [14, 15]. Bortezomib has been subsequently
demonstrated to act directly on PCs to induce apoptosis
through both caspases 8 and 9 activation, and it overcomes
the protective eﬀect of IL-6, and it acts synergistically with
Dexamethasone [16]. Similarly to IMiDs, bortezomib expli-
cates its activity on the bone marrow microenvironment in-
hibiting the PCs binding to stromal cells, the secretion of
growth factors, and myeloma-associated neoangiogenesis
[16].
The goal of CD34+ cell mobilization is to collect enough
cells to achieve a rapid and sustained hematopoietic recovery
after high-dose therapy, since delayed hematopoietic recov-
ery correlates with increased toxicity and transplant-related
mortality. It has been demonstrated that high CD34+ cell
doses (>3/5 × 106/kg) are associated with faster hematolog-
ical recovery and lower incidence of infectious and bleeding
complications [17]. Doses <2 × 106/kg are associated with
slower recovery and worse outcomes. CD34+ cell doses
over 15 × 106/kg after high-dose melphalan administration
can eliminate severe thrombocytopenia. The International
Myeloma Working Group (IMWG) has suggested a mini-
m u mt a r g e to f4× 106 and, if feasible, an average of 8–10 ×
106/kg that should be collected, allowing most myeloma
patients to undergo two autografts during the course of their
disease,alsoconsideringthatinsomepatients,theﬁrstASCT
can be unsuccessful [18].
We also evaluated the drug-related toxicity. Concerning
IMiDs, common side eﬀects are deep vein thrombosis
[19, 20] and related pulmonary embolism, neutropenia
and thrombocytopenia, peripheral neuropathy, fatigue, and
constipation. Bortezomib toxicity instead is mainly due to
peripheralneuropathyandthrombocytopenia[21].Diarrhea
and fatigue are also observed. VAD increased mortality
mainly due to systemic infections [22].
2.MaterialsandMethods
2.1. Patients. In this study, a total of 65 patients (44 men and
21 women), aged 48–65 years (median age 56.5 years), with
symptomatic MM (Durie-Salmon stage II/III) have been
evaluated (Table 1).
DatafromalladultpatientswithMM(n = 65)scheduled
for stem cell collection and subsequent ASCT between 2000
and 2011 at the Department of Biomedical Science and
Clinical Oncology, Section of Internal Medicine and Human
OncologyattheUniversityofBari,Italy,wereanalyzedinthis
retrospective study.
This study was approved by the Local Ethics Committee,
and all patients gave their informed consent according with
the Declaration of Helsinki.
2.2. Treatments. Induction therapy consisted of bortezomib-
based regimens (VTD [23], Vel-Dex [24], and PAD [25]);
Lenalidomide-based regimens (Len-Dex [26]); other regi-
mens (VAD [22], Thal-Dex [27, 28]).
VAD consisted of two 28-day cycles. Vincristine was ad-
ministered intravenously (i.v.) at the dose of 1mg/m2 on day
1; adriamycin 9mg/m2 on days 1–4; dexamethasone 40mg
daily on days 1–4.
VTD comprised four 3-week cycles of Bortezomib
1,3mg/m2 on days 1, 4, 8, and 11, thalidomide 100mg/day
for the ﬁrst 14 days and 200mg daily thereafter administered
orally, and dexamethasone at the same dose and schedule as
for the Vel-Dex regimen. Recommended concomitant medi-
cations included bisphosphonates, antibiotics, and antiviral
and antithrombotic prophylaxis in accordance with local
practice.
Thal-Dex was administered as four 35-day cycles, thal-






















































dexamethasone 40mg orally or i.v. on days 1–4, 9–12, and
17–20.
Len-Dex consisted of four 28-day cycles. Lenalidomide
was administered orally at the dose of 25mg on days 1–21
and dexamethasone orally at the dose of 40mg on days 1–8–
15–22.
Vel-Dex consisted of four 3-week cycles of bortezomib
1.3mg/m2 administered i.v. on days 1, 4, 8, and 11, plus
dexamethasone 40mg days 1–4 (all cycles) and 9–12 (cycles
1a n d2 ) .
PAD was administered as four 21-day cycles comprising
bortezomib 1,3mg/m2 i.v. on days 1, 4, 8, and 11, doxoru-
bicin at 30mg/m2 i.v. on days 1 to 4, and dexamethasone
40mg p.o., on days 1 to 4.
After induction therapy, all patients received a single
infusion of cyclophosphamide 4g/m2 followed by daily ad-
ministration of subcutaneous G-CSF at the dose of 10μg/kg
from day +5 until the peripheral stem cell harvest [29].
Nineteen patients received a second infusion of cyclophos-
phamide; of these, 8 patients received plerixafor as an addi-
tional mobilizing agent [30].
2.3. Response Criteria. Response, relapse, and progression
were assessed according to the European Bone Marrow
Transplant (EBMT) criteria [31]. CR was deﬁned as negative
serum and urine immunoﬁxation, <5% plasma cells in a
bone marrow aspirate as well as disappearance of soft tissue
plasmacytomas and no increase in lytic bone lesions. Partial
response (PR) was deﬁned as a decrease of serum M-protein
in ≥50%, 24-hour urinary light-chain excretion by ≥90% or
to<200mg,andreductionofextramedullaryplasmacytomas
in ≥50%. Minimal response (MR) required a reduction in
the level of serum protein between 25–49% and 50–89%
reduction in 24 hours urine light-chain protein excretion.
Responses should be maintained for a minimum of 6 weeks.
Relapse from CR was deﬁned as reappearance of serum
or urinary paraprotein on immunoﬁxation, development
of new extramedullary plasmacytomas, increase in size, or
developing of new lytic lesions or hypercalcemia. Progressive
disease required an increase in serum M-protein by >25%
with an absolute increase of at least 5g/L or increase in
urine M-protein by >25% and also an absolute increase
≥200mg/24h, and/or the appearance of soft-tissue plasma-
cytomas, new lytic bone lesions, or hypercalcemia.
2.4. Toxicity. A l lt h ea d v e r s ee v e n t sw e r ec o n s i d e r e dd u r i n g
the induction and mobilization period according to the
National Cancer Institute Common Toxicity Criteria (version
3.0).
2.5. Statistical Analysis. Data were analyzed with the SPSS
(Chicago, IL, USA) software package. All results are pre-
sented as median ±1 SD and range. The medians were
compared with the Mann-Whitney U test. P values < 0.005
were considered signiﬁcant. One-way ANOVA analysis was
used to compare all parameters between patients treated
with bortezomib or lenalidomide or other agents, also with
respect to response, number of collected cells, and toxicity.
3. Results and Discussion
3.1. Results of Mobilization and Leukapheresis. In VAD- and
Vel-treated patients, a signiﬁcantly higher CD34+ collection
was obtained: 8.5 ± 1.01 × 106 CD34+/Kg body weight (bw)
and 7.5 ± 1.08 × 106 CD34+/Kg bw, respectively, versus
4.11 ± 0.60 × 106 CD34+/Kg bw in lenalidomide-treated
patients (P = 0.01 and P<0.005) (Figure 1(a)). The4 Stem Cells International
Table 2: Adverse events.
Total adverse events Treated with bortezomib Treated with lenalidomide Treated with other agents
Fatigue 2 0 2 0
Deep vein thrombosis 1 0 1 0
Thrombocytopenia 13
Grade I/II 5 2
Grade III/IV 6
Anemia 11 0 9 2
Exacerbation of Crohn’s disease 1 0 1 0
Mucositis grade II 3 2 1 0
Nausea grade II 11 2 8 1
Diarrhea grade I/II 3 2 1 0
Dermatological toxicity 3 3 0 0
percentage of patients who reached the minimum collection
target after two leukaphereses was higher in those treated
with VAD or Vel (86% and 84%, resp.) than those treated
with lenalidomide (56%) (P<0.01). The apheresis’ mean
volume after plasma detraction was of 56 ± 16mL in VAD-
and Vel-treated patients and 53 ± 13mL in lenalidomide
treated patients.
3.2. Eﬃcacy. Overall response rate (ORR) was signiﬁcantly
better in Vel-based regimens (100% versus VAD 79%
and versus lenalidomide 83%). Particularly in VAD-treated
patients, we observe 4% of CR, 19% of PR, and 6% of stable
disease (SD). In Vel regimen, we found 5% of CR, 8% of
VGPR, and 5% of PR. Finally, response to lenalidomide was
2% of CR, 3% of very good partialresponse (VGPR), and 10%
of PR; 3% patients showed SD.
3.3. Adverse Events. Hematologic and nonhematologic tox-
icities are listed in Table 2. No peripheral neuropathy was
observed in all treatment regimens. Thrombocytopenia was
the most frequent observed side eﬀect and presented the
highest incidence in both the novel agent groups, although
in Len-treated patients, this was more serious (grade III/IV).
Anemia and nausea were also frequently observed. In this
retrospective analysis, the overall occurrence of adverse
events during treatment was higher in Len-based regimens.
3.4. Discussion. Data from several clinical trials have demon-
stratedthesuperiorityofnewagentseitherincombinationor
not with conventional chemotherapy as up-front therapy for
newlydiagnosedMMyoungpatients.Cavoetal.[32]showed
the pivotal role of IMiDs as primary therapy in preparation
for autologous transplantation compared with cytotoxic
protocols. The introduction of bortezomib in the 2000s
has dramatically changed the treatment options and the
clinical outcomes of both relapsed/refractory [33] and newly
diagnosed myeloma patients [24]. Furthermore, it has been
extensively clariﬁed that doublet therapies combining either
an IMiD or bortezomib with dexamethasone (i.e., Thal-
Dex or Len-Dex or Vel-Dex) aﬀected higher overall response
rates, progression free survival (PFS), and less toxicity than
traditional treatments [34–39]. Nevertheless, the Italian
group[23]inarandomizedphaseIIIstudyhasdemonstrated
that the combination of Vel-Thal-Dex (VTD) improves the
rate of CR and near-CR with no increase of relevant toxicity.
So, this combination can actually be considered the gold
standardforinductiontherapyinyoungertransplant-eligible
patients.
Lenalidomide is a more active analogue of thalidomide.
This provides the basis for its role in newly diagnosed MM
patients. When combined with dexamethasone and used
beyond four cycles, it achieves over 90% PR or better rate
[39]. A similar clinical trial in Europe had almost identical
results [26]. On the other hand, myelosuppression induced
by lenalidomide represents the dose-limiting toxicity and
requires monitoring during therapy. Similarly to thalido-
mide, lenalidomide is associated with increased incidence of
deep vein thrombosis and requires concurrent prophylactic
measures for its prevention [40, 41].
According to our data, the use of Vel-Dex regimen in
newly diagnosed patients has a strong impact in terms of
CR/nCR, VGPR, and ORR. Jagannath et al. [24]r e p o r t e d
18% CR and 88% ORR in a phase II study using combi-
nation of Vel-Dex in newly diagnosed MM patients. The
International Francophone Group against Myeloma (IFM) has
randomized 242 newly diagnosed patients to Vel-Dex or
VAD: CR/nCR were 15% versus 6% at least, VGPR 38%
versus 15%, and ORR 79% versus 63% after four cycles of
induction therapy. They observed signiﬁcantly higher ORR
with Vel-Dex compared with VAD [36].
In line with our observations, prolonged lenalidomide
induction therapy has been reported to aﬀect stem cell
mobilization. Patients undergoing peripheral blood stem cell
mobilization with G-CSF following lenalidomide induction
had signiﬁcant decrease in total CD34(+) cells collected,
average daily collection, and increased number of aphereses
[42].Theexactmechanismsbywhichlenalidomideinterferes
with stem cell mobilization are not clear. However, it seems
that there are no harmful eﬀects on the quality of PBSC
collected as denoted by similar engraftment rate across
all treatment groups. Nevertheless, here we observed that
the frequency and the seriousness of lenalidomide-inducedStem Cells International 5
adverse events are higher compared to those observed in the
Vel or other therapy-based regimens. Sekeres et al. [40]
estimatedthatmorethanhalfofpatientstreatedwithlenalid-
omide-based protocols developed grades 3 and 4 cytopenia,
mostly neutropenia and thrombocytopenia. Interestingly, it
has been shown that patients who develop severe hemato-
logic toxicity are more likely to better mobilize after cyclo-
phosphamide therapy, but mechanisms beyond this clinical
evidence remain still obscure. Contrarily, we did not observe
any Vel-related severe adverse events delaying ASCT. Based
on these reports, no more than six months of Lenalidomide
including regimen prior to Cyclophosphamide mobilization
should be recommended to avoid poor PBSC collection
[43]. However, the recent introduction of plerixafor which
increases the number of mobilized circulating hematopoietic
stem and progenitor cells when administered with G-CSF
may improve PBSC collection and change this scenario.
4. Conclusion
In the present study, we conﬁrm that to date a precise up-
front induction regimen for ASCT cannot be strongly
advised; each induction regimen presents some beneﬁts and
disadvantages thatshould be considered on the basisof med-
ical history and comorbidities of single myeloma patients.
However, novel antimyeloma drugs, mostly bortezomib- and
lenalidomide-based regimens, oﬀer a higher percentage of
ORR, and CR/nCR rate compared to other treatments based
on conventional agents. Notably, attainment of CR after
both induction therapy and ASCT is one of the strongest
predictors of long-term outcomes and represents a major
endpoint of current treatment strategies incorporating auto-
transplantation upfront. Among novel agents, bortezomib
containing associations oﬀer a better ORR, toxicity proﬁle,
and a higher probability to collect the minimum target of
CD34+.
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